Global Point of Care Diagnostics (POCD) Market Growth (Status and Outlook) 2023-2029

Global Point of Care Diagnostics (POCD) Market Growth (Status and Outlook) 2023-2029

Point of care tests, also called near-patient testing or bedside testing, refers to the performance of diagnostic tests at or near the site where the patient is located and helps in obtaining accurate results in a very short period of time.

LPI (LP Information)' newest research report, the “Point of Care Diagnostics (POCD) Industry Forecast” looks at past sales and reviews total world Point of Care Diagnostics (POCD) sales in 2022, providing a comprehensive analysis by region and market sector of projected Point of Care Diagnostics (POCD) sales for 2023 through 2029. With Point of Care Diagnostics (POCD) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Point of Care Diagnostics (POCD) industry.

This Insight Report provides a comprehensive analysis of the global Point of Care Diagnostics (POCD) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Point of Care Diagnostics (POCD) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Point of Care Diagnostics (POCD) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Point of Care Diagnostics (POCD) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Point of Care Diagnostics (POCD).

The global Point of Care Diagnostics (POCD) market size is projected to grow from US$ 25110 million in 2022 to US$ 47560 million in 2029; it is expected to grow at a CAGR of 9.6% from 2023 to 2029.

United States market for Point of Care Diagnostics (POCD) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Point of Care Diagnostics (POCD) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Point of Care Diagnostics (POCD) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Point of Care Diagnostics (POCD) players cover Alere, Roche, Abbott Laboratories, Johnson & Johnson, Siemens Healthcare, Danaher, QIAGEN, Bayer Healthcare and Beckman Coulter, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Point of Care Diagnostics (POCD) market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Blood Glucose Testing
Infectious Diseases Testing
Cardiac Markers Testing
Coagulation Testing
Pregnancy and Fertility Testing
Blood Gas/Electrolytes Testing
Tumor Markers Testing
Urinalysis Testing
Cholesterol Testing
Others

Segmentation by application
Clinics
Hospitals
Assisted Living Healthcare Facilities
Laboratory

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Alere
Roche
Abbott Laboratories
Johnson & Johnson
Siemens Healthcare
Danaher
QIAGEN
Bayer Healthcare
Beckman Coulter
Nipro Diagnostics
Bio-Rad Laboratories
Nova Biomedical
BioMerieux
Quidel
Helena Laboratories
OraSure Technologies
Accriva
Abaxis
Chembio Diagnostics
Trinity Biotech
Instrumentation Laboratory
Sekisui Diagnostics

Please note: The report will take approximately 2 business days to prepare and deliver.